Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 16 | 2026 | 881 | 2.370 |
Why?
|
| Mental Disorders | 3 | 2025 | 909 | 1.540 |
Why?
|
| Opioid-Related Disorders | 8 | 2026 | 293 | 1.530 |
Why?
|
| Osteogenesis Imperfecta | 5 | 2025 | 174 | 1.510 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2025 | 21 | 1.260 |
Why?
|
| Telemedicine | 3 | 2025 | 524 | 1.180 |
Why?
|
| Analgesics, Opioid | 7 | 2025 | 471 | 1.080 |
Why?
|
| Electronic Health Records | 4 | 2024 | 810 | 1.020 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2026 | 846 | 0.920 |
Why?
|
| Psychotherapy | 2 | 2025 | 246 | 0.920 |
Why?
|
| Empyema | 1 | 2022 | 24 | 0.770 |
Why?
|
| Evoked Potentials | 1 | 2022 | 126 | 0.720 |
Why?
|
| Algorithms | 3 | 2024 | 1686 | 0.690 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 97 | 0.670 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 279 | 0.650 |
Why?
|
| Sodium Lactate | 1 | 2019 | 3 | 0.600 |
Why?
|
| Computer Communication Networks | 1 | 2019 | 17 | 0.590 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 72 | 0.580 |
Why?
|
| Panic Disorder | 1 | 2019 | 53 | 0.570 |
Why?
|
| Clinical Coding | 1 | 2018 | 15 | 0.560 |
Why?
|
| Patient Discharge | 2 | 2020 | 512 | 0.540 |
Why?
|
| Carbon Dioxide | 1 | 2019 | 272 | 0.540 |
Why?
|
| Electroencephalography | 1 | 2022 | 875 | 0.540 |
Why?
|
| Medical Records | 1 | 2018 | 181 | 0.530 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 2308 | 0.530 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 228 | 0.520 |
Why?
|
| Phenotype | 2 | 2024 | 4531 | 0.450 |
Why?
|
| Opiate Substitution Treatment | 2 | 2026 | 39 | 0.450 |
Why?
|
| Medicaid | 3 | 2026 | 252 | 0.440 |
Why?
|
| Humans | 42 | 2026 | 131967 | 0.410 |
Why?
|
| Morphine | 2 | 2025 | 80 | 0.370 |
Why?
|
| Mental Health | 2 | 2026 | 384 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1413 | 0.360 |
Why?
|
| Pandemics | 4 | 2022 | 1165 | 0.360 |
Why?
|
| Adolescent | 14 | 2026 | 21008 | 0.350 |
Why?
|
| Tennessee | 3 | 2025 | 34 | 0.350 |
Why?
|
| Adult | 22 | 2026 | 31734 | 0.330 |
Why?
|
| Middle Aged | 17 | 2026 | 28911 | 0.310 |
Why?
|
| Young Adult | 12 | 2026 | 10108 | 0.310 |
Why?
|
| United States | 10 | 2026 | 11827 | 0.310 |
Why?
|
| Chronic Pain | 2 | 2024 | 164 | 0.300 |
Why?
|
| Aged | 10 | 2025 | 21279 | 0.290 |
Why?
|
| Depression | 3 | 2026 | 1352 | 0.280 |
Why?
|
| Female | 26 | 2026 | 71316 | 0.280 |
Why?
|
| Male | 24 | 2026 | 65357 | 0.280 |
Why?
|
| Reproducibility of Results | 6 | 2025 | 2992 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3095 | 0.260 |
Why?
|
| Psychometrics | 3 | 2025 | 678 | 0.250 |
Why?
|
| Culturally Competent Care | 2 | 2024 | 50 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2025 | 709 | 0.240 |
Why?
|
| Uncertainty | 2 | 2023 | 97 | 0.230 |
Why?
|
| Academic Performance | 1 | 2025 | 25 | 0.230 |
Why?
|
| Medically Uninsured | 1 | 2026 | 77 | 0.230 |
Why?
|
| Social Stigma | 1 | 2026 | 82 | 0.230 |
Why?
|
| Academic Success | 1 | 2025 | 22 | 0.230 |
Why?
|
| Insurance, Health | 1 | 2026 | 140 | 0.220 |
Why?
|
| Consumer Health Information | 1 | 2025 | 28 | 0.220 |
Why?
|
| Reward | 1 | 2025 | 117 | 0.220 |
Why?
|
| Adaptation, Psychological | 2 | 2025 | 437 | 0.220 |
Why?
|
| Benchmarking | 1 | 2025 | 138 | 0.210 |
Why?
|
| Hospitalization | 3 | 2024 | 1942 | 0.210 |
Why?
|
| Reproductive Health | 1 | 2024 | 48 | 0.210 |
Why?
|
| Retrospective Studies | 9 | 2026 | 17703 | 0.210 |
Why?
|
| Gender Identity | 1 | 2024 | 74 | 0.210 |
Why?
|
| Self Report | 2 | 2024 | 563 | 0.210 |
Why?
|
| Interview, Psychological | 1 | 2024 | 104 | 0.210 |
Why?
|
| Child | 10 | 2026 | 26332 | 0.200 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 116 | 0.200 |
Why?
|
| Buprenorphine | 1 | 2024 | 107 | 0.200 |
Why?
|
| Video Recording | 1 | 2025 | 208 | 0.200 |
Why?
|
| Students | 1 | 2025 | 251 | 0.200 |
Why?
|
| Incidence | 2 | 2022 | 3352 | 0.200 |
Why?
|
| Anticipation, Psychological | 1 | 2022 | 7 | 0.190 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 81 | 0.190 |
Why?
|
| Comorbidity | 2 | 2025 | 1607 | 0.190 |
Why?
|
| Implosive Therapy | 1 | 2024 | 103 | 0.190 |
Why?
|
| Family | 1 | 2025 | 593 | 0.180 |
Why?
|
| Pain Management | 1 | 2024 | 203 | 0.180 |
Why?
|
| Depressive Disorder | 1 | 2025 | 471 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2023 | 135 | 0.180 |
Why?
|
| Pregnancy | 5 | 2025 | 7577 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 325 | 0.170 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 176 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2021 | 252 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 6922 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2023 | 212 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2024 | 399 | 0.160 |
Why?
|
| Latin America | 3 | 2026 | 102 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2024 | 564 | 0.160 |
Why?
|
| Caregivers | 1 | 2025 | 585 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 189 | 0.150 |
Why?
|
| Fentanyl | 1 | 2019 | 54 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 442 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1030 | 0.140 |
Why?
|
| Methadone | 1 | 2019 | 126 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 61 | 0.140 |
Why?
|
| Quality of Life | 2 | 2026 | 2116 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 192 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 708 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2024 | 744 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 551 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2025 | 8604 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 475 | 0.120 |
Why?
|
| Genomics | 1 | 2023 | 1630 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 666 | 0.110 |
Why?
|
| Meningitis, Fungal | 1 | 2012 | 3 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2025 | 442 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 36 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2012 | 97 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2023 | 13011 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1362 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6522 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 314 | 0.080 |
Why?
|
| Infant | 2 | 2023 | 13332 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 350 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5122 | 0.080 |
Why?
|
| Financing, Government | 1 | 2026 | 33 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 4961 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 10 | 0.060 |
Why?
|
| Spain | 1 | 2025 | 62 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2025 | 29 | 0.060 |
Why?
|
| Data Accuracy | 1 | 2024 | 31 | 0.050 |
Why?
|
| Risk Factors | 1 | 2019 | 10998 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 157 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 235 | 0.050 |
Why?
|
| Transgender Persons | 1 | 2024 | 68 | 0.050 |
Why?
|
| Schools | 1 | 2025 | 240 | 0.050 |
Why?
|
| ROC Curve | 1 | 2025 | 622 | 0.050 |
Why?
|
| Cultural Competency | 1 | 2024 | 50 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 205 | 0.050 |
Why?
|
| Urban Population | 1 | 2024 | 281 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2024 | 230 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 375 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 260 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2023 | 184 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 195 | 0.040 |
Why?
|
| Electrodes | 1 | 2021 | 82 | 0.040 |
Why?
|
| Ventral Striatum | 1 | 2021 | 43 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2024 | 334 | 0.040 |
Why?
|
| Psychiatry | 1 | 2024 | 272 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2020 | 21 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2148 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1519 | 0.040 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 33 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 372 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2020 | 79 | 0.040 |
Why?
|
| Inpatients | 1 | 2024 | 544 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 230 | 0.040 |
Why?
|
| Cognition | 1 | 2024 | 845 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 838 | 0.040 |
Why?
|
| Metformin | 1 | 2020 | 168 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1400 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1307 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1173 | 0.030 |
Why?
|
| Parents | 1 | 2024 | 1120 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1840 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5298 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2026 | 4058 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3708 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 777 | 0.030 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2012 | 7 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 43 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 41 | 0.020 |
Why?
|
| Ascomycota | 1 | 2012 | 28 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2012 | 133 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3425 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3415 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 277 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2012 | 298 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 1049 | 0.010 |
Why?
|